地舒单抗在骨巨细胞瘤治疗中的地位

Denosumab in the treatment of giant cell tumor of bone

骨巨细胞瘤是原发交界性骨肿瘤,具有较高局部侵袭性和少见的远处转移性,主要好发于长骨的骨端,也会发生于较难治疗的隐匿部位如骨盆、骶骨和脊柱。骨巨细胞瘤的病理基础是由分泌表达RANKL的梭形基质细胞诱导和促进表达RANK的类破骨前体细胞融合形成多核巨细胞发挥溶骨作用,从而导致病理性骨质破坏。

Denosumab has significantly improved the treatment of giant cell tumor of bone since its emerging,however,surgery is still prioritized.Maximized value of denosumab as an adjuvant setting to surgery should be emphasized.Meanwhile,further researches on tumor cells and new drugs are still needed.